Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. - Wikidata - awgldk - TriplyDB

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

http://www.wikidata.org/entity/Q37098098

about

Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders Vascular Complications of Cancer Chemotherapy Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance Past strategies and future directions for identifying AMP-activated protein kinase (AMPK) modulators Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors Evaluation and management of patients with heart disease and cancer: cardio-oncology Hypertension in patients with cancer The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma Noninvasive imaging of cardiovascular injury related to the treatment of cancer Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity.Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives Potential Therapeutic Strategies for Hypertension-Exacerbated Cardiotoxicity of Anticancer Drugs Non-proliferative and Proliferative Lesions of the Cardiovascular System of the Rat and Mouse Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs Sunitinib in solid tumors Identification of a kinase profile that predicts chromosome damage induced by small molecule kinase inhibitors A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib Englerin a selectively induces necrosis in human renal cancer cells GSK-3alpha directly regulates beta-adrenergic signaling and the response of the heart to hemodynamic stress in mice Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies.Anti-alpha8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus.Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.Cardiomyocyte autophagy and cancer chemotherapy.Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention Sorafenib cardiotoxicity increases mortality after myocardial infarction.Brain natriuretic peptide precursor (NT-pro-BNP) levels predict for clinical benefit to sunitinib treatment in patients with metastatic renal cell carcinoma Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies.A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.

P2860

Q21261282-FBF1D174-2D91-4660-92CD-165528E10489 Q26743433-F973F7C2-5240-4AD9-8B3F-304D576BF830 Q26753129-F4B7A7EB-B13B-4D04-8681-330BD2FFFFF7 Q26766269-32319ECF-4756-4795-AA1F-A6D1C1472091 Q26859193-D846486A-507C-4D8C-BA80-4641A0BE7510 Q26864679-AC9BA07A-8B87-4898-993C-36CE250D17E9 Q26865766-4524D7AA-A7FF-4241-B137-110D63BD9510 Q26998273-814216FF-A742-4974-8CAF-AE29DC659395 Q27003980-ADBFD758-4097-420D-AE65-A3072D8EA667 Q27010466-A6AAD40D-AEC1-4235-9A47-ABF75B6C389B Q27011540-21AA6E23-9ABE-4F54-9F7A-C15D1E8C4A1E Q27013665-2DFAD7C1-F49F-4FFD-8291-A603CF9ED2FA Q27024715-5C3703EB-0DD6-43B1-AAFE-22D9FA9E3FCD Q27027354-679110A4-96D2-40E0-B214-257BCF94C832 Q28069560-76D09C77-C174-4489-9356-CE82AF8D3931 Q28070311-44B4F195-0084-4174-A565-C9AE515CAF83 Q28079801-B03D2083-D770-471C-A90E-6912CF373967 Q28087776-80F4EC75-66BD-44BE-82F0-58B5A7278699 Q28245467-8354B901-E9CE-4559-8A08-4FC4BE9270ED Q28475736-7AD96BA3-7EBE-4ED9-AA72-9773797F4F9A Q28476189-36EC81AE-FCA6-457C-BBD7-A65660A4218E Q28484574-8DA7B105-EC1F-4D32-854F-BA45EB1AAF0F Q28590516-67C57A30-8275-4096-89E4-185D9251CDC8 Q30234441-661911B0-C920-445A-A6C8-A51BE7A8563E Q30426853-9CE38937-D638-4647-9181-097E15D8ACF3 Q30437707-24B3AE4B-7571-407B-8499-DE8F93781E04 Q30446453-2C3D0EEA-E4D2-4EF7-BCBB-C88C0663EF37 Q30492863-72940558-88AB-4ACB-B1D6-56F6C1FC8E40 Q33395853-A7BD5BC4-5A3B-44BC-B240-C750C5C61C23 Q33404547-7A9C277E-AF1B-4A03-8CEC-D8138B27B3B3 Q33408049-709308B0-E08C-4D67-9267-4C19981F9CDE Q33420123-38E35949-661C-4C14-8834-7A0AC14E6348 Q33573823-E45AACA5-64BD-4D45-9AA0-3E12EEF8490F Q33574045-283B231E-FCB7-4AD0-BC60-B580DAAEED29 Q33681995-A3BF187F-0F6F-4323-9284-EA6EE4F0CEA7 Q33692402-8B9E6199-C4E7-474C-96B6-3FE929AF5236 Q33708158-4D4DB67D-D49B-4E78-AC99-5F5C19685501 Q33807542-6549C808-7063-47E2-9276-0D7977FDE6BE Q33812953-96BCC8FE-3BCF-4311-8792-1C96F6F1F687 Q33817421-93275777-ECA6-4058-9F87-1ECC8E8E0B73

P2860

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

http://www.wikidata.org/entity/Q37098098

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on December 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

@en

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

@nl

type

label

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

@en

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

@nl

prefLabel

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

@en

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

@nl

P1433

Q37098098-F52F0115-74E4-4999-9ABC-631BD99842AD

P1476

Q37098098-A0FDDD27-C98F-486B-AFA4-D8E57970DF4C

P2093

Q37098098-0D728465-42C1-436D-AD1B-FFE14E40C6DF

Q37098098-1905FA22-E583-4A93-8300-87D371195EFA

Q37098098-1920580A-4C56-4DD0-97C8-E183ED0D15B7

Q37098098-243E4F54-10B1-47D6-A58E-D607FF0EA818

Q37098098-2F2E5353-B76F-46BE-B2FE-B61B0F1770C1

Q37098098-407921B5-91F8-441F-A3EC-264CABAA7AC6

Q37098098-66F209B1-5F27-4AA0-A8E9-7A84532A8636

Q37098098-6903D1FF-40B3-46D3-A96E-0C3A4DDB4D27

Q37098098-7ECD82E8-92C7-4E42-BA42-84CA92B3B6A5

Q37098098-83241CD5-63A3-4E73-809F-AB462523B2CE

P2860

Q37098098-0DCADEEE-7DD4-4AF8-9797-D2174A6C0E21

Q37098098-21EC4C41-FB19-4105-BCFF-D5BFAD5EACF7

Q37098098-29FF9A00-8A3F-4B89-98DF-4E8C3C2734E9

Q37098098-2AD08D92-8FE7-48C4-8A73-0608354DD614

Q37098098-374C9E07-0C5D-45A7-AE16-B04D8F29BBE7

Q37098098-4437DC40-6D59-4710-8144-724800E0C99E

Q37098098-588CB7C2-1F3A-441E-BEBE-F82AA1A0AC4A

Q37098098-67B27AE2-83AD-41C4-8A7C-00E60F8DED2E

Q37098098-82966C50-6ABA-4172-9EE8-80D69BFEC735

Q37098098-8F7FD60C-9D35-4FB9-96BA-C47F456D47F0

P304

Q37098098-238F868D-99E6-4232-A058-4EA8AA51963F

P31

Q37098098-C3BEB412-59FB-47A5-A8AE-360DA2737EDD

P356

Q37098098-7C779EBE-732D-4A6B-800E-C44B88C39E69

P407

Q37098098-C219FC41-F432-45A8-BCFF-A67FFF9D7093

P433

Q37098098-2E0D5207-6B59-4878-850F-2060E0705D18

P478

Q37098098-98B723CF-1AA9-4B68-8274-4E8540A028D5

P50

Q37098098-67E69828-849D-4BF2-948F-08F201FDA129

P577

Q37098098-A054EAE2-24A9-4744-B3DF-2B927BCB9D45

P698

Q37098098-8D6BA880-2B5D-4F1C-8AC4-DD9AF9FFD65B

P932

Q37098098-33545EDB-0FC9-4BAD-9E1E-D99D13E831C4

P356

S0140-6736(07)61865-0

P1433

P1476

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.

@en

P2093

Annick D Van den Abbeele

http://www.w3.org/2001/XMLSchema#string

David M Harris

http://www.w3.org/2001/XMLSchema#string

Elke Pravda

http://www.w3.org/2001/XMLSchema#string

Flavia Cassiola

http://www.w3.org/2001/XMLSchema#string

Frederick J Schoen

http://www.w3.org/2001/XMLSchema#string

George D Demetri

http://www.w3.org/2001/XMLSchema#string

Jayesh Desai

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Morgan

http://www.w3.org/2001/XMLSchema#string

Jey-Hsin Chen

http://www.w3.org/2001/XMLSchema#string

Kathleen Woulfe

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

A small molecule-kinase interaction map for clinical kinase inhibitors

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Sunitinib in patients with metastatic renal cell carcinoma.

STRESS signaling pathways that modulate cardiac myocyte apoptosis.

ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 G

Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

P304

2011-2019

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0140-6736(07)61865-0

http://www.w3.org/2001/XMLSchema#string

P407

P433

9604

http://www.w3.org/2001/XMLSchema#string

P478

370

http://www.w3.org/2001/XMLSchema#string

P50

David Zurakowski

P577

2007-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18083403

http://www.w3.org/2001/XMLSchema#string

P932

2643085

http://www.w3.org/2001/XMLSchema#string